menu
    • menu

    Company profile for Catalent Pharma Solutions

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a global leader in providing integrated services, superior drug delivery technologies & manufacturing solutions to help life science innovators develop & launch successful pharmaceuticals, biologics and consumer health products, enabling a better customer journey from product development to patient. With over 85 years of experience in the industry, Catalent supports partners in introducing 200 new products and manufactu...
    We are a global leader in providing integrated services, superior drug delivery technologies & manufacturing solutions to help life science innovators develop & launch successful pharmaceuticals, biologics and consumer health products, enabling a better customer journey from product development to patient. With over 85 years of experience in the industry, Catalent supports partners in introducing 200 new products and manufacturing over 70 billion doses/year. We have grown to become a vibrant community of approximately 15,000 employees, including around 2,400 scientists and technicians, supporting over 7,000 products for over 1,000 customers.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Catalent Pharma SolutionsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    14 Schoolhouse Road, Somerset, NJ 08873
    Telephone
    Telephone
    +1 877-587-1835
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.catalent.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/catalent-pharma-solutions/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/catalentpharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    This week, SpeakPharma interviews Denise Sutton, Chief Operating Officer and Site Head at Quotient Sciences’ Nottingham facility in the UK. Quotient Sciences is a drug development and manufacturing accelerator that offers the innovative Translational Pharmaceutics platform to support customers in overcoming drug development challenges. Sutton has been with the company for over 25 years. In this interview, she provides insights into the evolution of Quotient Sciences’ Nottingham facility and discusses how the organization has transformed from a small 10-bed clinic to a comprehensive drug development campus with six GMP suites. She also shares her perspective on the company’s unique approach to integrating drug development services. HIGHLIGHTS// evolution of Quotient Sciences’ Nottingham facility/ unique approach to integrating drug development services How has the Nottingham site transformed from when it was founded, to what it is today? Initially, we were a small company with fewer than 50 employees, a 10-bed clinic, and a single lab. Over 90 percent of our work focused on gamma scintigraphic imaging (a diagnostic test that creates images of the body’s internal organs and tissues using gamma rays). Due to the short half-life radionuclides we used to label dosage forms, every product we manufactured had a limited time to be dosed. At the end of 1999, we moved our headquarters to a purpose-built, two-storey facility—now known as Trent House on our now much larger Nottingham campus. We built three good manufacturing practice (GMP) suites on the top floor and three clinical wards on the bottom floor. These were very early days that marked the start of our Translational Pharmaceutics platform. We continued to expand the range of scintigraphy applications we offered in response to changing customer requirements until, in 2008, when we approached the MHRA (UK’s Medicines and Healthcare products Regulatory Agency) with a new request. We asked if it might be possible to work at the same pace as we did in our scintigraphic imaging studies, but do so for conventional drug development, without the radiolabel. We explored the application of ICH Q8 Quality by Design (QbD) guidelines to introduce a compositional design space into the CMC section of our regulatory dossier. This officially created a methodology for applying the Translational Pharmaceutics platform, and we haven't looked back since. Today, we have expanded substantially. Our Nottingham site is a campus of five buildings. We have development and analytical labs, six GMP suites, six clinical wards with a total of 85 beds (where we conduct healthy volunteer phase 1 clinical studies), and many talented colleagues covering our spectrum of CRO and CDMO services. HIGHLIGHTS// officially created a methodology for applying the Translational Pharmaceutics platform/ development and analytical labs/ six GMP suites   How is Translational Pharmaceutics applied to drug development programs? We apply Translational Pharmaceutics across three core applications: first-in-human clinical studies, drug product optimization programs through rapid formulation development and clinical testing, and as a part of human ADME (absorption, distribution, metabolism, and excretion) programs. No matter how a client chooses to work with us to apply Translational Pharmaceutics, the benefits of using a single organization and project management team to integrate services lets our clients remain in control and one step ahead of the emerging data that impacts the success of their molecule. Over all these years, our flagship Translational Pharmaceutics platform for drug development has remained unchanged in the way it empowers our customers and offers them unparalleled flexibility. HIGHLIGHTS// three core applications/ benefits of using a single organization/ clients remain in control   What would you say are the key strengths of Quotient Sciences’ Nottingham site? How do you support customer programs? Nowhere else would a single project manager oversee such a broad spectrum of activities, let alone be expected to ensure seamless, timely progression across functions that in any other company (i.e. at other CDMOs or CROs) would be delivered through multiple operating areas or through the use of a combination of third-party vendors. The project managers do face challenges. But by working with the project team, they are able to anticipate, avoid, and mitigate any impact whenever necessary. We know that time is incredibly valuable for our customers. A project Gantt chart is our project management team’s guiding light. I believe our project management team is truly world-leading – they communicate well, show great compassion, and lead with integrity. I’m super proud of our high-performing, supportive, cross-functional teams that support our customers when they trust their molecules to us, and work collaboratively to deliver the best possible service. After 25 years at Quotient, I continue to really enjoy going to work. I am indebted to various colleagues for helping me continue to feel this way. HIGHLIGHTS// project management team is truly world-leading/ high-performing, supportive, cross-functional teams/ 25 years at Quotient  

    Impressions: 4916

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility

    Radio Compass
    16 Dec 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    BMS, J&J, Bayer lead 25,000+ pharma layoffs in 2024; Amylyx, FibroGen, Kronos Bio hit by trial failures, cash crunch

    BMS, J&J, Bayer lead 25,000+ pharma layoffs in 2024; Amylyx, FibroGen, Kronos Bio hit by trial failures, cash crunch

    Since 2022, there has been a significant surge in layoffs by pharmaceutical and biotech companies. While this trend continued into 2024, the industry showed signs of stabilization in the last four months of the year with the pace of layoffs slowing down. Nonetheless, 2024 was a challenging year. Data compiled by PharmaCompass indicates that over 25,000 layoffs were announced in 2024, driven by economic pressures, failed clinical trials, and strategic pivots. Bristol Myers Squibb and Johnson & Johnson led the layoffs with about 2,300 job cuts each. Bayer announced elimination of 1,800 positions.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available) US, Europe, China bear brunt of job cuts; Big Pharma hands pink slips to 10,000 Over 190 biopharma companies announced layoffs in 2024. The year began on a grim note — 27 firms announced significant job cuts in January 2024. By the yearend, Big Pharma alone had contributed more than 10,000 layoffs to the year’s total of over 25,000. Novartis announced over 1,200 job cuts in 2024. It eliminated 330 jobs after it acquired German biotech MorphoSys through the closure of sites in Munich and Boston. Similarly, Bayer announced significant reductions at its US and Swiss facilities.  North America saw increased retrenchments, especially at biotech hubs such as Boston, San Diego, and New Jersey. Massachusetts, with Boston and Cambridge as the epicenter of US biotechnology, saw around 4,000 layoffs, with companies like Relay Therapeutics, Editas Medicine, and Takeda driving the numbers. In San Diego, workforce reductions by Takeda, and Bavarian Nordic collectively resulted in over 900 job losses, significantly impacting the local biotech ecosystem. New Jersey was subject to broader restructuring efforts with BMS and Bayer contributing nearly 1,500 layoffs. The impact in Europe was equally severe. Germany, home to some of the world’s largest pharmaceutical companies, saw over 2,500 layoffs as Bayer and Boehringer Ingelheim scaled back operations. Novartis’ decision to shut down its Munich site added hundreds more to the tally. In Switzerland, Idorsia eliminated 270 positions. Dutch biotech UniQure reduced its workforce by 65 percent (around 300 jobs). That included the sale of a Massachusetts manufacturing facility to Genezen. Denmark also felt the strain, with Leo Pharma cutting 250 roles as part of a strategic revamp. China emerged as another focal point of workforce reductions in 2024. Global pharmaceutical giants, such as Merck and Johnson & Johnson, restructured their operations in response to market complexities in the region. Local companies such as Connect Biopharma, which is transitioning to a US-focused company, also scaled back their presence in the country.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Amylyx, FibroGen, Lyra, Athira drastically reduce staff over setbacks in clinical trials Clinical trial failures were one of the most significant drivers of layoffs in 2024. For instance, Amylyx Pharmaceuticals faced a devastating blow when its amyotrophic lateral sclerosis (ALS) therapy, Relyvrio, failed a confirmatory trial. This led to a 70 percent reduction in its workforce, leaving only 100 employees from the 384 full-time staff reported at the end of 2023. The company’s decision to pull the therapy from the market compounded the layoffs. BioMarin Pharmaceutical had to reduce its workforce, as it streamlined its pipeline in response to trial challenges. In August, the company announced a reduction of 225 employees, citing “organizational redesign efforts”. These layoffs followed 170 redundancies announced earlier in May. FibroGen, once considered a leader in oncology drug development, was among the most heavily impacted. The high-profile failure of its anti-CTGF antibody in two late-stage cancer trials led to the discontinuation of its lead candidate, resulting in a 75 percent reduction in its US workforce. Lyra Therapeutics also implemented a 75 percent workforce reduction, affecting 87 employees, after its chronic rhinosinusitis program struggled. Similarly, Athira Pharma cut 70 percent of its team after its Alzheimer’s candidate failed a phase 2/3 trial.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Cash crunch, mergers compel Kronos Bio, Editas, Vincerx, Gilead to downsize In addition to clinical failures, funding constraints played a pivotal role in reshaping the biotech landscape. Kronos Bio stood out as one of the hardest-hit firms, cutting 21 percent and 83 percent of its existing workforce in March and November, respectively, as it sought to divest assets and conserve cash. Editas Medicine’s inability to secure partnerships for its sickle cell program forced the company to revert to preclinical research, resulting in a 65 percent workforce reduction. The trend of scaling back R&D pipelines was particularly evident among biotechs struggling to advance preclinical programs to clinical trials. Boundless Bio and Senti Bio exemplified this, choosing to focus on a handful of promising candidates, while reducing discovery efforts. Consolidation often results in overlapping roles, leading to inevitable workforce reductions. Apart from the MorphoSys layoffs by Novartis, Vincerx Pharma faced job losses after it got acquired by Oqory (a clinical-stage ADC company). Vincerx had to cut its workforce by 55 percent.  Amid ongoing reorganization efforts, Gilead closed its Seattle, Washington (US), office and laid off 72 employees of its subsidiary Kite Pharma. Gilead also announced that its Kite facility in Philadelphia, Pennsylvania (US), would close by mid-2025. That was followed by 104 additional layoffs at its California headquarters. In April, it had cut 58 jobs in California. Gilead also announced that its Kite facility in Philadelphia would close by mid-2025. Vir Biotechnology reduced its workforce by 25 percent (i.e. 140 layoffs) to focus on its hepatitis program, and GlycoMimetics let go of 80 percent of its workforce after the FDA demanded an additional clinical trial for its leukemia treatment. Meanwhile, Lexicon Pharmaceuticals reduced its workforce by 60 percent after it stopped commercial operations and transitioned back to being a clinical stage company.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Our view It takes decades to build innovation ecosystems. The concentration of layoffs in major biotech hubs has raised concerns about the potential long-term impact on these ecosystems. In 2025, the key challenge will be to maintain the momentum of innovation, as organizations operate with a leaner workforce and a more focused pipeline.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4560

    https://www.pharmacompass.com/radio-compass-blog/bms-j-j-bayer-lead-25-000-pharma-layoffs-in-2024-amylyx-fibrogen-kronos-bio-hit-by-trial-failures-cash-crunch

    #PharmaFlow by PHARMACOMPASS
    16 Jan 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Novo Holdings Completes Acquisition of Catalent
    Novo Holdings Completes Acquisition of Catalent

    18 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241218507326/en

    BUSINESSWIRE
    18 Dec 2024
    Share Share
    Regulatory conditions on Novo $16.5 billion Catalent deal fulfilled
    Regulatory conditions on Novo $16.5 billion Catalent deal fulfilled

    16 Dec 2024

    // PRESS RELEASE

    https://www.catalent.com/catalent-news/catalent-and-novo-holdings-fulfill-all-regulatory-closing-conditions-for-pending-transaction/

    PRESS RELEASE
    16 Dec 2024
    Share Share
    Novo holding Clears Catalent Buy & 3 Novo Nordisk Sites Acquisitions
    Novo holding Clears Catalent Buy & 3 Novo Nordisk Sites Acquisitions

    14 Dec 2024

    // PRESS RELEASE

    https://www.catalent.com/catalent-news/catalent-and-novo-holdings-fulfill-all-regulatory-closing-conditions-for-pending-transaction/

    PRESS RELEASE
    14 Dec 2024
    Share Share
    Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval
    Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval

    09 Dec 2024

    // PRESS RELEASE

    https://www.catalent.com/catalent-news/catalent-and-novo-holdings-receive-european-commission-unconditional-approval-for-pending-transaction/

    PRESS RELEASE
    09 Dec 2024
    Share Share
    Novo Holdings set to win EU nod for $16.5 bln Catalent deal
    Novo Holdings set to win EU nod for $16.5 bln Catalent deal

    23 Nov 2024

    // REUTERS

    https://www.reuters.com/markets/deals/eu-antitrust-regulators-set-okay-165-bln-novo-holdings-catalent-deal-source-says-2024-11-22/

    REUTERS
    23 Nov 2024
    Share Share
    EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
    EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal

    13 Nov 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulators-quiz-novo-nordisk-catalent-rivals-165-bln-deal-2024-11-13/

    REUTERS
    13 Nov 2024
    Share Share

    USDMF

    read-more
    read-more

    01

    Accutane (10mg, 40mg)

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    02

    Advil Cold And Sinus Liquid Gels

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    03

    Advil Liqui-gels, 200 Mg

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    04

    Advil Pm Liqui-gels

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    05

    Amprenavir 50 And 150 Mg Soft Gelati...

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    06

    Amr101 1g Capsules

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    07

    Atrasentan Hydrochloride, Soft Gelat...

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    08

    Calcitriol 0.25 Mcg Soft Gelatin Cap...

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    09

    Calderol Softgels 20mcg

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow

    10

    Drisdol Softgels (ergocalciferol, 50...

    U.S.A
    BIO Partnering at JPM
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Siren Biotechnology and Catalent Partner to Manufacture AAV Gene Therapies for Cancer

    Details:

    The partnership aims to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies, being developed for the treatment of cancer.


    Lead Product(s): AAV-based Therapy

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Cell and Gene therapy

    Sponsor: Siren Biotechnology

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership May 08, 2024

    blank

    01

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AAV-based Therapy

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Siren Biotechnology

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Siren Biotechnology and Catalent Partner to Manufacture AAV Gene Therapies for Cancer

    Details : The partnership aims to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies, being developed for the treatment of cancer.

    Brand Name : Undisclosed

    Molecule Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    May 08, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for its Zydis® Fast-Dissolve Technology for Use in MELT-300 fo...

    Details:

    Under the agreement, Melt Pharmaceuticals will utilize Catalent’s proprietary Zydis® orally disintegrating tablet fast-dissolve technology with MELT-300 (midazolam), a sublingual, needle- and opioid-free patented formulation for procedural sedation during cataract surgery.


    Lead Product(s): Midazolam,Ketamine Hydrochloride

    Therapeutic Area: Neurology Brand Name: Melt-300

    Study Phase: Phase IIProduct Type: Small molecule

    Sponsor: Melt Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement September 26, 2023

    blank

    02

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Midazolam,Ketamine Hydrochloride

    Therapeutic Area : Neurology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Melt Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for its Z...

    Details : Under the agreement, Melt Pharmaceuticals will utilize Catalent’s proprietary Zydis® orally disintegrating tablet fast-dissolve technology with MELT-300 (midazolam), a sublingual, needle- and opioid-free patented formulation for procedural sedation du...

    Brand Name : Melt-300

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    September 26, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    MindMed Announces Exclusive License Agreement with Catalent for its Patented Zydis® Fast-Dissolve Technology for Use with MM-120

    Details:

    Under the agreement, Catalent has granted MindMed access to its Zydis technology for the development of MindMed’s lead candidate MM-120 (lysergide D-tartrate), which is currently in Phase 2 for generalized anxiety disorder.


    Lead Product(s): Lysergide D-tartrate

    Therapeutic Area: Psychiatry/Psychology Brand Name: MM-120

    Study Phase: Phase IIProduct Type: Small molecule

    Sponsor: Mind Medicine

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement August 03, 2023

    blank

    03

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lysergide D-tartrate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Mind Medicine

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    MindMed Announces Exclusive License Agreement with Catalent for its Patented Zydis® Fast-Dissolve...

    Details : Under the agreement, Catalent has granted MindMed access to its Zydis technology for the development of MindMed’s lead candidate MM-120 (lysergide D-tartrate), which is currently in Phase 2 for generalized anxiety disorder.

    Brand Name : MM-120

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    August 03, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Harm Reduction Therapeutics and Catalent Sign Commercial Supply Agreement for Naloxone Nasal Spray to Reverse Opioid Overdoses

    Details:

    Under the agreement, Catalent will manufacture Harm Reduction Therapeutics’ naloxone nasal spray, RiVive™, for the emergency treatment of known or suspected opioid overdose.


    Lead Product(s): Naloxone Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Brand Name: Rivive

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Harm Reduction Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement March 23, 2023

    blank

    04

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naloxone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Harm Reduction Therapeutics

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Harm Reduction Therapeutics and Catalent Sign Commercial Supply Agreement for Naloxone Nasal Spray...

    Details : Under the agreement, Catalent will manufacture Harm Reduction Therapeutics’ naloxone nasal spray, RiVive™, for the emergency treatment of known or suspected opioid overdose.

    Brand Name : Rivive

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    March 23, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Catalent and Grünenthal Announce Successful Collaboration to Facilitate Expedited Clinical Development Timelines

    Details:

    The collaboration leads to the successful reformulation of an investigational, orally dosed small molecule in Grünenthal’s pipeline to improve its bioavailability. Phase 1 studies of the molecule will be supported by using the Catalent Xpress Pharmaceutics™ platform.


    Lead Product(s): Undisclosed

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Small molecule

    Sponsor: Grunenthal

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration March 15, 2023

    blank

    05

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Neurology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Grunenthal

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Catalent and Grünenthal Announce Successful Collaboration to Facilitate Expedited Clinical Develo...

    Details : The collaboration leads to the successful reformulation of an investigational, orally dosed small molecule in Grünenthal’s pipeline to improve its bioavailability. Phase 1 studies of the molecule will be supported by using the Catalent Xpress Pharmace...

    Brand Name : Undisclosed

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    March 15, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Incannex Engages Catalent to Develop and Manufacture cGMP-Grade Psilocybin Drug Products for Clinical Trials and Potential Commercial Use

    Details:

    PSI-GAD (psilocybin) reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety effects.


    Lead Product(s): Psilocybine

    Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Small molecule

    Sponsor: Incannex Healthcare

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 06, 2023

    blank

    06

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Psilocybine

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Incannex Healthcare

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Incannex Engages Catalent to Develop and Manufacture cGMP-Grade Psilocybin Drug Products for Clini...

    Details : PSI-GAD (psilocybin) reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-a...

    Brand Name : Undisclosed

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    March 06, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Catalent and Ethicann Sign Development and License Agreement for New Fast-Dissolve Cannabinoid-Based Treatments

    Details:

    Under the terms of the license agreement, Catalent and Ethicann will develop Ethicann’s clinical drug pipeline using Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology including EPI-002 (cannabinoid) candidate to treat MS spasticity.


    Lead Product(s): Cannabinoid

    Therapeutic Area: Musculoskeletal Brand Name: EPI-002

    Study Phase: PreclinicalProduct Type: Small molecule

    Sponsor: Ethicann Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement January 12, 2023

    blank

    07

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cannabinoid

    Therapeutic Area : Musculoskeletal

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Ethicann Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Catalent and Ethicann Sign Development and License Agreement for New Fast-Dissolve Cannabinoid-Bas...

    Details : Under the terms of the license agreement, Catalent and Ethicann will develop Ethicann’s clinical drug pipeline using Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology including EPI-002 (cannabinoid) candidate to treat MS sp...

    Brand Name : EPI-002

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    January 12, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®

    Details:

    INBRIJA® (levodopa) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa. INBRIJA utilizes ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation.


    Lead Product(s): Etilevodopa

    Therapeutic Area: Neurology Brand Name: Inbrija

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Acorda Therapeutics

    Deal Size: $10.0 million Upfront Cash: Undisclosed

    Deal Type: Agreement January 05, 2023

    blank

    08

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Etilevodopa

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Acorda Therapeutics

    Deal Size : $10.0 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®

    Details : INBRIJA® (levodopa) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa. INBRIJA utilizes ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inha...

    Brand Name : Inbrija

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    January 05, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate

    Details:

    SRP-9001 (delandistrogene moxeparvovec) is an investigational gene transfer therapy intended to deliver SRP-9001 to muscle tissue for the targeted production of essential components of dystrophin.


    Lead Product(s): Delandistrogene Moxeparvovec

    Therapeutic Area: Genetic Disease Brand Name: SRP-9001

    Study Phase: Phase IIIProduct Type: Cell and Gene therapy

    Sponsor: Sarepta Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement January 05, 2023

    blank

    09

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Delandistrogene Moxeparvovec

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Sarepta Therapeutics

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement f...

    Details : SRP-9001 (delandistrogene moxeparvovec) is an investigational gene transfer therapy intended to deliver SRP-9001 to muscle tissue for the targeted production of essential components of dystrophin.

    Brand Name : SRP-9001

    Molecule Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    January 05, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs

    Details:

    Exelixis will fund the development work conducted by Catalent until development candidate selection is complete, after which Exelixis will assume responsibility for conducting preclinical, clinical, and commercial activities.


    Lead Product(s): Antibody-drug Conjugate

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: DiscoveryProduct Type: Large molecule

    Sponsor: Exelixis

    Deal Size: Undisclosed Upfront Cash: $30.0 million

    Deal Type: Licensing Agreement November 03, 2022

    blank

    10

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Catalent Pharma Solutions

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Antibody-drug Conjugate

    Therapeutic Area : Oncology

    Highest Development Status : Discovery

    Partner/Sponsor/Collaborator : Exelixis

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs

    Details : Exelixis will fund the development work conducted by Catalent until development candidate selection is complete, after which Exelixis will assume responsibility for conducting preclinical, clinical, and commercial activities.

    Brand Name : Undisclosed

    Molecule Type : Large molecule

    Upfront Cash : $30.0 million

    November 03, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Services

    Upload your portfolio for free, ask us

    Analytical

    Click here to discover the service providers for Analytical

    API Manufacturing

    Click here to discover the service providers for API Manufacturing

    Drug Product Manufacturing

    Click here to discover the service providers for Drug Product Manufacturing

    Sales, Marketing, Registration

    Click here to discover the service providers for Sales, Marketing, Registration

    Clinical Trials

    Click here to discover the service providers for Clinical Trials

    API & Drug Product Development

    Click here to discover the service providers for API & Drug Product Development

    Packaging

    Click here to discover the service providers for Packaging

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Catalent Pharma Solutions and get a quotation

    Catalent Pharma Solutions is a supplier offers 67 products (APIs, Excipients or Intermediates).

    Find a price of Hyaluronidase bulk with JDMF offered by Catalent Pharma Solutions

    Find a price of Ibuprofen bulk with DMF offered by Catalent Pharma Solutions

    Find a price of Selegiline Hydrochloride bulk with DMF offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET-10275378] bulk with DMF offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET - 10275485] bulk with DMF offered by Catalent Pharma Solutions

    Find a price of Amprenavir bulk offered by Catalent Pharma Solutions

    Find a price of Atrasentan bulk offered by Catalent Pharma Solutions

    Find a price of Benzonatate bulk offered by Catalent Pharma Solutions

    Find a price of Bexarotene bulk offered by Catalent Pharma Solutions

    Find a price of Calcifediol bulk offered by Catalent Pharma Solutions

    Find a price of Calcitriol bulk offered by Catalent Pharma Solutions

    Find a price of Cyclosporine bulk offered by Catalent Pharma Solutions

    Find a price of Doxcercalciferol bulk offered by Catalent Pharma Solutions

    Find a price of Dutasteride bulk offered by Catalent Pharma Solutions

    Find a price of Enzalutamide bulk offered by Catalent Pharma Solutions

    Find a price of Estradiol bulk offered by Catalent Pharma Solutions

    Find a price of Ethosuximide bulk offered by Catalent Pharma Solutions

    Find a price of Ibuprofen bulk offered by Catalent Pharma Solutions

    Find a price of Icosapent Ethyl bulk offered by Catalent Pharma Solutions

    Find a price of Isotretinoin bulk offered by Catalent Pharma Solutions

    Find a price of Lopinavir bulk offered by Catalent Pharma Solutions

    Find a price of Loratadine bulk offered by Catalent Pharma Solutions

    Find a price of Lubiprostone bulk offered by Catalent Pharma Solutions

    Find a price of Miconazole bulk offered by Catalent Pharma Solutions

    Find a price of Miconazole Nitrate bulk offered by Catalent Pharma Solutions

    Find a price of Nifedipine bulk offered by Catalent Pharma Solutions

    Find a price of Nimodipine bulk offered by Catalent Pharma Solutions

    Find a price of Omega-3-Acid Ethyl Esters 90 bulk offered by Catalent Pharma Solutions

    Find a price of Palonosetron bulk offered by Catalent Pharma Solutions

    Find a price of Paricalcitol bulk offered by Catalent Pharma Solutions

    Find a price of Progesterone bulk offered by Catalent Pharma Solutions

    Find a price of Risperidone bulk offered by Catalent Pharma Solutions

    Find a price of Ritonavir bulk offered by Catalent Pharma Solutions

    Find a price of talarozole bulk offered by Catalent Pharma Solutions

    Find a price of Terazosin HCl bulk offered by Catalent Pharma Solutions

    Find a price of Tetrahydrocannabinol bulk offered by Catalent Pharma Solutions

    Find a price of Tipranavir bulk offered by Catalent Pharma Solutions

    Find a price of Tretinoin bulk offered by Catalent Pharma Solutions

    Find a price of Vitamin D bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET-10275282] bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET-10275266] bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET 10275449 50] bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET-10275260] bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET-10259015-17] bulk offered by Catalent Pharma Solutions

    Find a price of MICRONIZATION PROCESS FACILITY bulk offered by Catalent Pharma Solutions

    Find a price of CONTRACT MICRONIZATION FACILITY IN KENT, UNITED KINGDOM bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET-10259014] bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET-10275198] bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET-10275265] bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET-10275261] bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET - 10258984] bulk offered by Catalent Pharma Solutions

    Find a price of WC3042-05, CAPSULE bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET-10275412] bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [0775279] bulk offered by Catalent Pharma Solutions

    Find a price of LANOXICAPS (0.5, 0.10, AND 0.20MG) SOFTGEL CAPSULES bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET- 10275405-7] bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET-10275268] bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET-00775174] bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET-10275547-9] bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGEL CAPSULE [OET-10275263] bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET: 10275427-9] bulk offered by Catalent Pharma Solutions

    Find a price of WC3042-08P CAPSULE bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET-10258867] bulk offered by Catalent Pharma Solutions

    Find a price of CONTRACT MICRONIZATION FACILITY IN EXTON, PA. bulk offered by Catalent Pharma Solutions

    Find a price of YXSORALEN-ULTRA SOFT GELATIN CAPSULES bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET-10275191] bulk offered by Catalent Pharma Solutions

    Find a price of SOFTGELS [OET-10275226] bulk offered by Catalent Pharma Solutions

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search